SNDX NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Syndax Pharmaceuticals Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 20.81 USD
-8.7% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -2.5% below the Trend Line and sits at 70.4% of its 52-week range. The latest completed week returned -8.7%, after a -2.3% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is bullish with 40/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 2d.

Setup score 40 out of 100
Latest Close 20.81 USD 24 Jul 2026
1W Return -8.7% latest completed week
4W Return -2.3% short-term follow-through
12W Return 8.9% quarterly tape
Trend Breadth 69.2% 36 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -8.7% Latest completed week; four-week move -2.3%. Indicator stack 38/55 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 40/100 conviction; expected move 14.5%. News sentiment 56/100 60 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -2.5% below the Trend Line and sits at 70.4% of its 52-week range. The latest completed week returned -8.7%, after a -2.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3512-week average 0.42

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.35Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers33 reversal markers

No recent accumulation markers. 3 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -2.3% over four weeks, 8.9% over 12 weeks, and 116.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-8.7%
4W-2.3%
12W8.9%
26W2.8%
52W116.1%
Active trend streak0 weeks
Active weeks in one year36
Trend breadth69.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.11Latest activity-pressure read.
Pressure change88.4%Four-week change in activity pressure.
Leadership-0.53Latest relative-leadership reading.
RS change-121.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength13/100Blend of value, momentum, and quality. Underlying universe rank 88; rank 1 is best.
Value12/100Relative valuation strength. Underlying universe rank 89; rank 1 is best.
Quality3/100Profitability and accounting quality. Underlying universe rank 98; rank 1 is best.
Momentum95/100Medium-term price momentum. Underlying universe rank 6; rank 1 is best.
Growth90/100Revenue and earnings growth. Underlying universe rank 11; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
8.5x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-13.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
98.0%
Gross profit retained from each unit of revenue.
Operating margin
-74.9%
Operating profit retained from revenue.
Free-cash-flow margin
-128.0%
Free cash flow generated from revenue.
Return on invested capital
-47.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
396.7%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-1.1%
Net share repurchases relative to market value.
Shareholder yield
-1.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

SNDX shows bullish options pressure with a 40/100 conviction score, put-call volume ratio of 0.50, expected move of 14.5%, and Sharemaestro trend signal inactive.

Conviction40/100
Expected move14.5%
Put/call volume0.50
Pressure44
Speculation30
Volatility96
Trend agreement21
Open options detail
Insider activity6 / 5

6 acquisitions and 5 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 60 relevant articles.

19 positive · 35 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
Options expected move14.5%Nearest-chain priced movement where available.
52-week drawdown-18.7%Distance below the 52-week high.
13-week volatility7.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+12.5%Week of 8 May.
Worst week-11.7%Week of 24 Apr.
Latest week-8.7%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains5
Flat weeks0
Modest losses8
Sharp losses5
Recent vol7.8%13-week weekly-return volatility.
Base vol7.7%52-week weekly-return volatility.
Up/down split30/21Count of positive and negative weeks in the 52-week window.
Average skew6.5% / -4.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape39/100

Trend, activity pressure, participation, and risk combine to a 39/100 tape read.

 Indicator analysis21/100

Latest 12-week confirmation: trend 2/12, activity pressure 0/12, relative leadership 5/12.

Activity pressure 0.35; 3 reversal markers Factors27/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 77; Small Cap Core rank 90 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options48/100

SNDX shows bullish options pressure with a 40/100 conviction score, put-call volume ratio of 0.50, expected move of 14.5%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 14.5% Sentiment56/100

Weighted news tone is neutral across 60 relevant articles.

Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Healthcare of Ontario Pension Plan Trust Fund Insiders6 / 5

6 acquisitions and 5 disposals in the latest 180-day insider tape.

 Earnings2d

Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202620.81 USD-8.7%21.34 USD17.82 USD-0.11-0.536.1MOff
17 Jul 202622.80 USD-3.4%21.35 USD17.82 USD-0.158.158.4MOff
10 Jul 202623.61 USD8.2%21.28 USD17.81 USD-0.408.4311.4MOff
3 Jul 202621.82 USD2.4%21.18 USD17.80 USD-0.773.0211.0MOff
26 Jun 202621.31 USD12.2%21.13 USD17.79 USD-0.962.4311.2MOff
19 Jun 202619.00 USD4.1%21.08 USD17.78 USD-1.17-12.0010.0MOff
12 Jun 202618.25 USD5.2%21.02 USD17.80 USD-1.27-12.777.8MOff
5 Jun 202617.34 USD-11.5%20.97 USD17.81 USD-1.21-14.8814.6MOff
29 May 202619.59 USD-1.8%20.89 USD17.84 USD-1.14-7.993.8MOff
22 May 202619.94 USD-1.4%20.70 USD17.84 USD-1.03-3.245.6MOff
15 May 202620.23 USD-5.9%20.48 USD17.84 USD-0.80-0.089.1MOn
8 May 202621.49 USD12.5%20.29 USD17.85 USD-0.466.609.2MOn
1 May 202619.11 USD-10.7%20.11 USD17.85 USD-0.190.5711.2MOn
24 Apr 202621.39 USD-11.7%19.99 USD17.86 USD0.2114.328.5MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.